These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 17230226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.
    Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
    [Abstract] [Full Text] [Related]

  • 3. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

  • 6. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, Serve H.
    Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
    [Abstract] [Full Text] [Related]

  • 7. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ, Xue J, Corey SJ.
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [Abstract] [Full Text] [Related]

  • 8. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT, Levis M, Small D.
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [Abstract] [Full Text] [Related]

  • 9. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 10. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 11. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA, Kazi JU, Rönnstrand L.
    Oncotarget; 2016 Mar 01; 7(9):9964-74. PubMed ID: 26848862
    [Abstract] [Full Text] [Related]

  • 12. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 01; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 13. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, Stone R.
    Cancer Res; 2005 Aug 15; 65(16):7338-47. PubMed ID: 16103085
    [Abstract] [Full Text] [Related]

  • 14. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.
    Ann Hematol; 2016 Apr 15; 95(5):783-91. PubMed ID: 26891877
    [Abstract] [Full Text] [Related]

  • 15. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
    Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, Matsushita T, Kaibuchi K, Senga T, Kojima T, Kohno T, Hamaguchi M, Naoe T.
    Eur J Haematol; 2011 Mar 15; 86(3):191-8. PubMed ID: 21114537
    [Abstract] [Full Text] [Related]

  • 16. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.
    Blood; 2012 Apr 26; 119(17):4026-33. PubMed ID: 22411868
    [Abstract] [Full Text] [Related]

  • 17. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 26; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 18. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
    Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, Shimizu M, Arai H, Ishii K, Akinaga S, Naoe T.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4575-82. PubMed ID: 17671144
    [Abstract] [Full Text] [Related]

  • 19. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
    Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, Levis MJ, Neckers L, Trepel JB.
    Leukemia; 2007 Dec 01; 21(12):2476-84. PubMed ID: 17851558
    [Abstract] [Full Text] [Related]

  • 20. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
    Seedhouse CH, Pallis M, Grundy M, Shang S, Russell NH.
    Br J Haematol; 2009 Dec 01; 147(5):653-61. PubMed ID: 19775300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.